clinical trials motor neurone disease

clinical trials motor neurone disease

BING based on image search results

BING based on video search results

BING based search results

  • clinical trials motor neurone disease
  • Edaravone acts as a ‘free radical scavenger’ helping to reduce the effects of oxidative stress (as explained in a post on our research blog). The first Phase 3 clinical trial of edaravone in MND found no overall benefit in people with MND, but showed an improvement in breathing function in a subgroup of people with an early form of the disease.
  • https://www.mndassociation.org/research/about-mnd-research/clinical-trials/treatment-trials/

  • clinical trials motor neurone disease
  • The clinical trials listed in the database are collected from a range of sources, including the Australian New Zealand Clinical Trials Registry listed above. ClinicalTrials.gov is the United States (US) National Institutes of Health’s (NIH) database of private and public clinical trials conducted in the US and elsewhere around the world.
  • https://www.mndaust.asn.au/Discover-our-research/Latest-research/Clinical-trials.aspx

  • clinical trials motor neurone disease
  • Update: July 2019 The initial results of the Lighthouse Project Phase 2 clinical trial have just been released. What is the Lighthouse Project? The Lighthouse Project is to test whether human endogenous retroviruses (HERVs) may play a role in motor neurone disease (MND) and whether targeting HERVs might provide a novel therapeutic avenue.
  • https://www.mndaust.asn.au/Discover-our-research/Latest-research/Clinical-trials/The-Lighthouse-Project.aspx

  • clinical trials motor neurone disease
  • (viii) Current participation in a clinical trial which in the opinion of the chief investigator might impact the objectives of this study. Exclusion criteria for Benign Fasciculation Syndrome patients: (i) Significant diagnostic uncertainty, whereby motor neurone disease remains a possible differential diagnosis.
  • https://www.clinicaltrials.gov/ct2/show/NCT03809845

  • clinical trials motor neurone disease
  • 2018 Research Update: Clinical Trials. A summary of research from the 2018 Australasian MND Symposium. This information will be of interest to neurologists and researchers with an interest in MND, and people affected by MND who have a strong interest in scientific research.
  • https://mnd.org.nz/2018-research-update-clinical-trials/

  • clinical trials motor neurone disease
  • Urbi B, Broadley S, Bedlack R, Russo E, Sabet A. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
  • https://clinicaltrials.gov/ct2/show/NCT03690791

  • Motor neuron disease
  • Motor neurone disease (MND), sometimes referred to as amyotrophic lateral sclerosis (ALS) , is the name given to a group of progressive neurological conditions where specific nerve cells, or neurons, don’t work normally. This leads to increasing physical disability, as muscles are unable to receivee messages from the neurons to move or activate.
  • https://www.florey.edu.au/diseases-disorders/motor-neurone-disease

  • clinical trials motor neurone disease
  • This study is intended to obtain clinical information and establish a repository of DNA, RNA, peripheral blood monocyte, lymphocyte and skin tissue samples from people with ALS and related neurodegenerative motor neuron diseases, people with a family history of these conditions, and healthy people with no family history of these disorders.
  • https://www.mayo.edu/research/clinical-trials/diseases-conditions/motor-neuron-disease

  • clinical trials motor neurone disease
  • CARE-MND is a platform to integrate clinical care with research for people with motor neurone disease across Scotland. The CARE -MND platform integrates clinical care, audit, research and evaluation to provide ongoing comprehensive monitoring of every person living with MND in Scotland.
  • https://www.care-mnd.org.uk/

  • clinical trials motor neurone disease
  • For use in clinical trials, a surrogate end point would be of great value. A surrogate end point is defined as a biomarker that is intended to substitute for a known clinical end point, such as survival in the case of motor neuron disease.
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897051/